Evidence map›Paper›PMID 38895057›Full record

ArticleEJHaem2024

Eculizumab for Shiga-toxin-induced hemolytic uremic syndrome in adults with neurological involvement.

Benjamin J Lee, Zhaohui Arter, Jean Doh, Shawn P Griffin, Pongthep Vittayawacharin, Steven Atallah, Kevin R Shieh, Minh-Ha Tran, Sonata Jodele, Piyanuch Kongtim and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Benjamin J LeeDepartment of Pharmacy University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0002-1678-1345
Zhaohui ArterDepartment of Medicine Division of Hematology-Oncology Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.
Jean DohDepartment of Pharmacy University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0003-2737-5243
Shawn P GriffinDepartment of Pharmacy University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0002-3818-2490
Pongthep VittayawacharinDepartment of Medicine Division of Hematology-Oncology Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0002-1131-5564
Steven AtallahDepartment of Pharmacy University of California Irvine Health Orange California USA.
Kevin R ShiehDepartment of Medicine Division of Hematology-Oncology Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0003-4339-2967
Minh-Ha TranDepartment of Pathology and Laboratory Medicine Division of Transfusion Medicine University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0002-9974-5277
Sonata JodeleDivision of Bone Marrow Transplantation and Immune Deficiency Cancer and Blood Disease Institute Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.ORCID https://orcid.org/0000-0002-1791-7718
Piyanuch KongtimDepartment of Medicine Division of Hematology-Oncology Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0003-2130-7645
Stefan O CiureaDepartment of Medicine Division of Hematology-Oncology Chao Family Comprehensive Cancer Center University of California Irvine Health Orange California USA.ORCID https://orcid.org/0000-0001-8597-3271

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

The role of eculizumab in treating Shiga-toxin-producing

Indexed as

eculizumabhemolytic uremic syndromeneurological involvementShiga‐toxin producing Escherichia coliSTEC‐HUS

Identifiers

PMID38895057
PMCPMC11182416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.